(Bloomberg) -- Pfizer Inc. has acquired exclusive rights to commercialize an obesity therapy in China, strengthening its push into the fast-growing weight loss market. The American drugmaker struck a ...

Pfizer secured a reprieve from President Donald Trump’s long-threatened tariffs on the pharmaceutical industry by agreeing to ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

(Bloomberg) -- Pfizer Inc. is drawing on lessons learned years ago from rolling out Viagra as it maps out the launch of its first obesity medicine. The parallels between weight loss and erectile ...

Pfizer (PFE) fell ~5% on Tuesday as Wall Street analysts assessed mid-stage data the company posted for its obesity therapy PF-08653944 ahead of its consensus-beating Q4 2025 results, which indicated ...

Pfizer (PFE) shares fell in the premarket on Tuesday after the company reaffirmed its full-year outlook, indicating a revenue contraction for 2026 amid a nearly $1.5B impact attributed to some of its ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Pfizer Inc. forecast little to no sales growth next year as the drugmaker undertakes an effort to refresh its pipeline of hit drugs with a series of pricey acquisitions. Revenue in 2026 will be $59.5 ...